Problems continue with the quality standards at manufacturing plants in India. This time it’s Sun Pharma that appears to be in trouble with the FDA imposing a Warning Letter for operations at the company’s Halol facility.
During the FDA inspection more than 20 manufacturing quality violations were noted.
What does this mean for the Long Term viability of India’s generic industry? With so many company’s now under some form of restitution and/or import ban will America consumers start to exert their buying power to demand drugs from reliable sources? Furthermore, where does this leave American Pharmaceutical companies that are sourcing these products from Indian companies? Are they in danger of a consumer backlash?